SHPH 8-K SEC Filing Analysis

Latest settled — T+20d

SHPH ▼ -22.98% at T+20d

SHORT call ✓ call won +22.98% · α vs SPY +28.26% · entry $0.6920 → $0.5330

Next anchor: T+60d in 6w

Currently $3.91 · -465.03% from $0.6920 entry (call sign-flipped)

Entry anchored
May 1, 09:23 AM ET
via Databento tick

T+1d

+19.51%

call -19.51% · α -19.85%

$0.8270

settled 6w ago

T+5d

+2.02%

call -2.02% · α +0.32%

$0.7060

settled 5w ago

T+20d

-22.98%

call +22.98% · α +28.26%

$0.5330

settled 12d ago

T+60d

—

call — · α —

—

in 6w

Price Chart

Loading chart...

Executive Summary

Shuttle Pharmaceuticals entered into a merger agreement with United Dogecoin Inc., a dogecoin mining company, and concurrently raised $11M through a PIPE offering of Series B-2 Convertible Preferred Stock and warrants. The transaction represents a transformative shift from pharmaceuticals to crypto mining, but existing SHPH shareholders face massive dilution as the merger consideration grants United Dogecoin holders 75.65% of the pro forma equity on an as-converted basis.

Key Financial Metrics

Offering Size

$11.0M

Actionable Insight

The reverse merger into crypto mining with heavy dilution suggests existing shares will be significantly revalued. Monitor stockholder approval and Nasdaq listing conditions. The milestone earnout shares add further overhang. Traders should expect high volatility and potential downside for legacy SHPH holders.

Key Facts

Entry into Merger Agreement with United Dogecoin Inc., a dogecoin mining company
PIPE offering of $11M in Series B-2 Convertible Preferred Stock plus warrants for 100% warrant coverage at $1.03 per share
Merger consideration: United Dogecoin stockholders receive 75.65% of the combined entity on an as-converted basis, excluding PIPE shares
Up to 32.6M additional milestone shares issuable for achieving mining rig purchase, uptime, and power cost targets
Existing SHPH market cap is only $6M; the transaction is massively dilutive to current shareholders
No revenue or financial figures for either company disclosed in the filing

Financial Impact

PIPE gross proceeds of $11,000,000, but existing shareholders diluted to approximately 24.35% on an as-converted basis

dilution

Risk Factors

Massive dilution to existing shareholders: legacy stake reduced to ~24% on pro forma basis
Stockholder approval and Nasdaq listing requirements may not be met
Milestone conditions for earnout shares are speculative and may not be achieved
Integration and execution risk in transitioning from pharma to crypto mining
No financial statements for United Dogecoin provided; valuation opaque

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001493152-26-020830
Exhibit: ex2-1.htm	0001493152-26-020830

4 reports for SHPH

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for SHPH — sortable, filterable
	Type				Now
Jun 11, 2026 1d ago	8-K NEUTRAL ★ 3/10	$4.27 awaiting T+20	awaiting T+20	—	$3.91 (−8.43%)
May 7, 2026 5w ago	8-K BEARISH ★ 8/10	$0.6890 $0.4540	▲ +34.11%	▲ +34.13%	$3.91 (−467.49%)
May 1, 2026 6w ago	8-K BEARISH ★ 7/10	$0.6920 $0.5330	▲ +22.98%	▲ +28.26%	$3.91 (−465.03%)
Mar 10, 2026 13w ago	8-K NEUTRAL ★ 4/10	$0.9010 $0.7250	▼ −19.53%	▼ −20.06%	$3.91 (+333.96%)

US Market Status

Market Closed — Opens Mon (49h 37m)

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access